Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Needham raised its price target for Stryker (NYSE: SYK) to $454 from $448 and kept a Buy rating after the company posted fourth-quarter results that beat consensus. The quarter showed improving organic sales growth and margin expansion at the operating level, while management provided 2026 guidance that aligns with street expectations but flags a $…
Needham raised its price target on Deckers Outdoor to $138 from $115 and kept a Buy rating after the footwear maker reported fiscal third-quarter 2026 results that beat expectations. Deckers recorded 7% revenue growth and $3.33 in EPS for the quarter, lifted its full-year sales and EPS guidance, and drew upgraded forecasts and target changes from o…
Electro Optic Systems (EOS) is preparing to relocate its headquarters and stock-market listing from Australia to Europe within a year, its CEO said, citing accelerating demand across the continent for laser-based drone-defence systems and worries among governments about where intellectual property is held. The company has already secured a 71 milli…
USCB Financial Holdings President and CEO Luis De La Aguilera sold 10,000 Class A shares on January 29, 2026, for $180,200 and exercised options to acquire 10,000 shares the same day. The transactions leave him with 245,893 directly owned shares and several option tranches. The firm reported mixed fourth-quarter 2025 results that missed analyst exp…
ProMIS Neurosciences announced a private placement agreement that could generate up to $175 million, sending its stock up 24%. The initial gross proceeds are expected to be about $75 million, with another $100 million possible if warrants issued in the deal are fully exercised. Management and institutional investors are participating; closing is ta…
Rosenblatt lowered its price objective on Calix to $70 from $85 while keeping a Buy rating following the company’s fourth-quarter 2025 results and mixed first-quarter guidance. Calix reported record quarterly and annual revenue, but management warned of rising memory costs that are expected to affect shipments after the first quarter and will likel…
The Swiss National Bank (SNB) has denied engaging in any manipulation of the Swiss franc after the U.S. Treasury kept Switzerland on a watch list for potential currency management. The Treasury said it is expanding monitoring of foreign exchange practices, including interventions that counter both depreciation and appreciation versus the U.S. dolla…
Palladyne AI pairs hardware robotics with autonomy software and a recent cybersecurity partnership. The market is pricing the company like a growth software story while revenue proof is still emerging. We think a mid-term long trade captures re-rating potential from new contract wins and recurring software sales, while respect for headline valuatio…
Israel said it will reopen the Rafah border crossing with Egypt on Sunday for people traveling between Gaza and Egypt, marking the first reopening of the crossing since it was seized in May 2024. The Israeli civil coordination body COGAT said returns will be limited to Gaza residents who left during the war and will require prior Israeli security c…
Microsoft has been weak on AI anxiety headlines, but beneath the headlines the company still posts strong cloud growth, a massive $625B commercial backlog, $77.4B in free cash flow and a fortress balance sheet. The market is trading off near-term execution fears; that creates a tactical buy opportunity for a swing trade with defined risk.
With fourth-quarter earnings on the horizon, BofA Securities has identified a set of companies it believes are well placed to manage AI-driven disruption, tighter cost discipline and uneven enterprise IT spending. The bank highlights a large-cap software leader supported by resilient cloud demand and several niche winners across travel software, fi…
Wedbush reaffirmed an Outperform rating and a $350 price target for Apple following the company’s fiscal first-quarter 2026 results. The quarter featured notable iPhone strength, particularly in China, and guidance that outpaces Street expectations, while analysts highlight an uncounted AI premium and elevated valuation multiples.
UBS maintained a Neutral rating and a $19.00 price target on Energizer Holdings Inc. (ENR) ahead of the company's fiscal first-quarter results on February 5. The firm projects Q1 EPS of $0.25, noting pressures from difficult year-ago comparisons tied to storm-driven demand and early display shipment headwinds. Despite a low P/E and a sizable divide…
Rosenblatt Securities raised its 12-month price target for Apple to $267 from $250 while maintaining a Neutral rating. The adjustment follows a fiscal first-quarter 2026 beat driven by stronger-than-expected iPhone demand and improved gross margins, even as Rosenblatt and other firms weigh valuation and potential margin pressures.
Mizuho increased its 12-month price target for Eastman Chemical (EMN) from $68.00 to $75.00 while retaining an Outperform rating. The lift in the target reflects higher market and peer valuation multiples even as the company reported softer fourth-quarter 2025 operating results and issued conservative near-term EPS guidance amid macro uncertainty.
Rosenblatt Securities reduced its price target for Elastic N.V. (ESTC) to $110 from $130 but retained a Buy rating, pointing to recent comparable multiple compression and macroeconomic concerns affecting enterprise software. The stock trades near its 52-week low, while the company has announced product advances including Agent Builder and AWS-focus…
Wedbush has reaffirmed an Outperform rating and a $340.00 price target for Amazon.com (AMZN) ahead of the company’s fourth-quarter earnings report scheduled for February 5. The firm raised its operating income estimates, highlighted accelerating demand and capacity additions at Amazon Web Services (AWS), and said continued strong AWS performance co…
Bernstein SocGen Group raised its price objective for SanDisk to $1,000 from $580 and kept an Outperform rating after the company reported second-quarter revenue and non-GAAP EPS that beat consensus. Management's third-quarter revenue and margin guidance drove the analyst's sharper outlook and prompted similar target increases from several peers, w…
D. Boral Capital lowered its rating on Quince Therapeutics Inc. (QNCX) from Buy to Hold after the company reported negative Phase 3 results for its eDSP program in Ataxia-Telangiectasia. The stock plunged sharply, management has stopped clinical development of eDSP, and the company is pivoting toward conserving cash and evaluating strategic options…
Preliminary data from the national statistics institute show Mexico's economy grew 0.8% in the fourth quarter of 2025, outpacing consensus and reversing a contraction in Q3. On an annual basis Q4 GDP rose 1.6%, and the full-year expansion for 2025 was 0.5%, exceeding central bank and analyst forecasts. Agriculture was the strongest performing secto…
Bank of America reiterated a Buy rating on Snowflake, calling the AI-focused data cloud vendor one of the fastest growing stories in software. The bank raised its price target to $275 and said Snowflake is well positioned to benefit from rising enterprise spending on data analytics and AI, though the stock trades at a significant premium to peers.
Regeneron Pharmaceuticals reported fourth-quarter adjusted earnings that exceeded analyst expectations, driven by robust demand for the eczema medication Dupixent. While Dupixent sales climbed substantially, Eylea revenue fell sharply amid competitive pressures and regulatory delays tied to a manufacturing facility. Sanofi warned that Dupixent will…
Goldman Sachs began coverage of Kerry Group with a buy recommendation, assigning a 12-month target price of €95 versus an initiation price of €73.45 and highlighting a recent multi-year portfolio transformation that left Kerry as a pure-play ingredients supplier. The report points to improved margins after the divestiture of Dairy Ireland, a heavy …
H.C. Wainwright raised its price target on Protagonist Therapeutics to $117.00 from $80.00 and retained a Buy rating, citing the commercial and financial implications of a rusfertide New Drug Application submitted by Takeda and Protagonist. The firm expects the company will likely opt out of a profit-sharing arrangement, unlocking substantial upfro…
H.C. Wainwright increased its price target for Praxis Precision Medicines Inc. (PRAX) to $1,245 from $340 while keeping a Buy rating, citing higher peak sales expectations for ulixacaltamide and relutrigine. The firm highlights relutrigine as a potential broad-use therapy with projected peak sales of $6.8 billion and points to forthcoming clinical …
